

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)



(10) International Publication Number
WO 2022/253156 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
C12N 15/13 (2006.01) *A61P 35/00* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2022/095841

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

30 May 2022 (30.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/097239

31 May 2021 (31.05.2021) CN

PCT/CN2021/097240

31 May 2021 (31.05.2021) CN

PCT/CN2021/106783

16 July 2021 (16.07.2021) CN

PCT/CN2021/106784

16 July 2021 (16.07.2021) CN

(71) Applicant: SHIJIAZHUANG YILING PHARMA-
CEUTICAL CO., LTD. [CN/CN]; No.238, Tianshan
Street Hi-Tech. Development District, Shijiazhuang, Hebei
050035 (CN).

(72) Inventor: JIA, Zhenhua; No.238, Tianshan Street Hi-
Tech. Development District, Shijiazhuang, Hebei 050035
(CN).

(74) Agent: WU, FENG & ZHANG; 3 FL, Building 2, Yard 3,
FengXiuZhongLu Road, Haidian District, Beijing 100094
(CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: MONOCLONAL ANTIBODIES AGAINST CLDN18.2 AND FC-ENGINEERED VERSIONS THEREOF

(57) Abstract: A panel of monoclonal antibodies which specifically bind to CLDN18.2 and do not specifically bind to CLDN18.1, and optionally have an engineered Fc region is provided.

WO 2022/253156 A1